For answers to questions about clinical trials at the Wellmont Cancer Institute or for more information about a specific study listed here, please contact one of the clinical trials experts.
Female newly diagnosed breast cancer stage 1-3
Adjuvant or neoadjuvant chemotherapy
Female: PS 0-1; Invasive Breast Cancer; pT1-3; pN0, pN1; pN2a, pN2b; pN3a or pN3b; If pN0 must be one of the following :
pTx and ER- and PgR negpT2 and ER+ and either grade 3 or Oncotype Dx > 25
Her 2 status evaluated prior to randomization as HER2 low IHC staining of 1+ (ISH testing is not required) or 2+ FISH or CISH must also be performed and must indicate no more than 84 days post op
Adenocarcinoma of the prostate within 180 days prior to registration; clinically negative nodes within 90 days by imaging; M0; No testosterone within 90 days.
High Risk:Gleason Score > 9 and PSA < 150 and Any T stageGleason Score 8 and PSA < 20 and T stage > T2Gleason Score 8 and PSA > 20-150 and Any StageGleason Score 7 and PSA > 20-150 and Any T Stage
No prior Hormonal Therapy estrogens or surgical castration; No prior radiation therapy
Diagnosis within 180 days: moderate to high risk:
Gleason score 7-10 + T1c-T2b+PSA<50Gleason Score 6+T2c-T4 or >50% positive biopsies+PSA<50Gleason Score + T1c-T2b +PSA >20
No prior surgery, radiation, hormone ablation
Several web-based resources have been developed to facilitate patient access to and information about clinical trials performed in hospitals and clinics around the country. Searchable databases of national clinical trials are also available through the National Cancer Institute and the Southeast Cancer Control Consortium.
You clicked on a link that will cause you to leave myWellmont.
For security purposes you will be signed out.